干细胞治疗勃起功能障碍的研究进展  

Stem cell therapy for erectile dysfunction:An update

作　　者：栾焦晨 张其杰(综述) 夏佳东[1] 宋宁宏(审校)[1] LUAN Jiao-chen;ZHANG Qi-jie;XIA Jia-dong;SONG Ning-hong(Department of Urology,The First Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu 210029,China)

机构地区：[1]南京医科大学第一附属医院泌尿外科,江苏南京210029

出　　处：《中华男科学杂志》2021年第3期256-261,共6页National Journal of Andrology

基　　金：国家自然科学基金(81871151,81971377)。

摘　　要：ED是常见的男科疾病,传统的药物常常不能达到满意的治疗效果。而干细胞疗法是生物医学的新领域,近年来针对其治疗ED的研究数量显著增加。本文主要包含了干细胞治疗ED的临床前研究及相关临床研究,临床前研究的动物模型主要分为糖尿病、阴茎海绵体损伤、老龄化和阴茎硬结症性ED。既往研究表明干细胞主要以旁分泌的方式改善阴茎的勃起功能,且其联合治疗比单独治疗更能改变ED的相关病理变化。虽然目前有关干细胞治疗ED的临床试验已部分证实了其安全性和有效性,但仍处于早期阶段,且样本量较少。本文就最新的研究证据总结干细胞治疗ED的相关进展。Erectile dysfunction(ED)is a common andrological disorder,and traditional oral drugs often fail to achieve satisfactory therapeutic effects.As a new field of biomedicine,stem cell therapy(SCT)has seen a significantly increasing number of researches on its treatment of ED in recent years.Preclinical animal models for the study of ED mainly include the models of diabetes mellitus-,aging-,cavernous nerve injury-,and Peyronie’s disease-related ED.Previous studies indicated that SCT improved erectile function through paracrine and was more effective when combined with other therapies than used alone in restoring ED-induced pathological changes.Although clinical trials on SCT have partially proved its safety and effectiveness for the treatment of ED,they were still in the early stages and with relatively small sample sizes.This article summarizes the latest advances in the treatment of ED by SCT.

关 键 词：勃起功能障碍 干细胞 糖尿病 海绵体神经损伤 老龄 阴茎硬结症 

分 类 号：R698.1[医药卫生—泌尿科学]